Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
87.66
+1.57 (1.82%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 21 analysts with 12-month price forecasts for Blueprint Medicines stock have an average target of 124.48, with a low estimate of 76 and a high estimate of 168. The average target predicts an increase of 42.00% from the current stock price of 87.66.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Blueprint Medicines stock from 22 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 6 | 6 | 7 | 7 |
| Buy | 7 | 7 | 7 | 7 | 8 | 8 |
| Hold | 5 | 5 | 5 | 5 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 19 | 20 | 19 | 19 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $128 | Buy | Reiterates | $128 | +46.02% | Apr 16, 2025 |
| Needham | Needham | Strong Buy Reiterates $133 | Strong Buy | Reiterates | $133 | +51.72% | Apr 8, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $120 → $100 | Hold | Initiates | $120 → $100 | +14.08% | Mar 20, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $135 | Strong Buy | Initiates | $135 | +54.00% | Mar 17, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $150 | Buy | Initiates | $150 | +71.12% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
737.03M
from 508.82M
Increased by 44.85%
Revenue Next Year
973.29M
from 737.03M
Increased by 32.06%
EPS This Year
-1.19
from -1.07
EPS Next Year
1.19
from -1.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 854.7M | 1.1B | 1.5B | ||
| Avg | 737.0M | 973.3M | 1.2B | ||
| Low | 683.1M | 835.9M | 904.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 68.0% | 50.6% | 58.7% | ||
| Avg | 44.8% | 32.1% | 26.3% | ||
| Low | 34.2% | 13.4% | -7.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.76 | 4.11 | 7.58 | ||
| Avg | -1.19 | 1.19 | 4.04 | ||
| Low | -2.20 | -1.46 | 0.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 535.5% | ||
| Avg | - | - | 238.7% | ||
| Low | - | - | -30.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.